Evofem Biosciences Inc

NASDAQ:EVFM  
0.41
-0.69 (-63.14%)
Products

Evofem Presents Data Detailing Fewer Urinary Tract Infections In Women Using Phexxi

Published: 05/06/2022 13:56 GMT
Evofem Biosciences Inc (EVFM) - Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 Ampower Clinical Trial.
Evofem Biosciences Inc - Adverse Events Were Congruent With Results From Overall Study Findings.
Evofem Biosciences-new Data From Phase 3 Ampower Clinical Trial of Phexxi Showed Women Enrolled in Trial Had Fewer Utis Compared to General Population.